Noachis Terra is using a novel technology to develop a coronavirus vaccine that is effective at protecting humans from the SARS-CoV-2 virus and preventing COVID-2019.

The technology is based upon a stabilized protein construct maintaining a prefusion state combine with a novel adjuvant to produce a robust immune response to the SARS-CoV-2 virus. The vaccine itself will require one to doses to provide a lifetime of immunity.


The SARS-CoV-2 virus causes COVID-19 which has resulted in severe disease and death in the human population. The highly stable prefusion construct specifically focuses the immune system on the highly immunogenic region of the virus that binds with the host cell for replication, resulting in a robust immune response to the wild virus. The vaccine also has the potential to provide a reaction to those already infected with the virus.


Laboratory testing of the constructs shows highly immunogenic response to the protein construct. Vaccine is in animal testing at present with preliminary results showing high immunogenic response and potential effectiveness against other coronavirus strains as well.



Since its discovery in December 2019 in the Wuhan province of China, SARS-CoV-2 has been discovered in more than 60 countries, close to 170,000 individuals and has caused more than 6,500 deaths. Transmission rates are high. The highest risk population for developing severe COVID-19 are those age 65 and older and those with underlying health conditions, such as diabetes and cardiovascular disease.

There is no vaccine currently on the market preventing infection from SARS-CoV-2.  Multiple therapies are in research and development at present.

Technology is currently in animal testing. Pre-clinical development expected to commence April 2020, with IND filing in 3Q.



The vaccine is currently in the pre-clinical stage with expectations of entering into clinical trials by October 2020.

Need more details?

Contact us for more information

© 2020 Noachis Terra, Inc.